Piper Sandler assumed coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $76 price target The firm cites the potential of ALXN1840, a treatment for Wilson disease, for the Overweight rating. Monopar plans to file approval for ALXN1840 by early 2026 and Piper sees “strong odds of FDA approval, citing the Phase 3 data and the unmet need in Wilson disease specifically in patients with neurologic symptoms. It believes ALXN1840 has “significant value creating potential” for shareholders.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR: